Children in focus: Two new research groups are investigating collaboration and supply structures for the promotion of mental health among children and adolescents

Gruppenfoto Ideas Lab Fotocredit: Scott Middleton

The starting shot for the research programme ‘Mental Health of Children and Adolescents’ was given! In late May 2017, a several-day Ideas Lab was held in Schlosspark Mauerbach. The aim was to establish an interdisciplinary research programme on the topic of ‘children of mentally ill parents’. The concept of ‘talking WITH rather than ABOUT the people affected’ played a major role in shaping the Ideas Lab and the further involvement of those affected and their family members in the research project.


Reduced mobilization of fat contributes to metabolic health

Obesity and unhealthy diets trigger a variety of health problems, including type 2 Diabetes with more than 60,000,000 Europeans suffering from it. Pharmaceutical companies have long been seeking for therapeutic interventions to protect from the health problems associated with the metabolic syndrome. A team led by Richard Moriggl from the Ludwig Boltzmann Institute for Cancer Research has now discovered a molecular mechanism that might be suitable as target for such a therapy.

Project: Arrest Blindness

The Ludwig Boltzmann Society (LBI Trauma) is partner in a just started 2020 Health EC project within regenerative medicine (PHC 16 call) 2016-2019.

The project “Arrest Blindness” deals with Eye Cornea Regeneration/Replacement by tissue engineering technology. This project was one of 6 (out of 312 applications) which were funded. Of such new therapies about 200.000 patients/year (Europe only) could benefit.

Press Release: HIV scientists launch 23 million euro project to develop vaccine

Vienna, 2nd of November 2014 - A new 23 million euro initiative to accelerate the search for an effective HIV vaccine begins today.

Financed by the European Commission, the European AIDS Vaccine Initiative (EAVI2020) brings together leading HIV researchers from public organisations and biotech companies from across Europe, Australia, Canada and the USA in a focused effort to develop protective and therapeutic HIV vaccines.

Welcome! Two new LBI will carry out their research under the roof of the LBG

From left to right: Barbara Weitgruber, Federal Ministry of Science, Research and Economy, Markus Mitterhauser, Director of the LBI for Applied Diagnostics, Kaan Boztug, Director of the LBI for Rare and Undiagnosed Diseases, Claudia Lingner, General Manager of the LBG and Josef Pröll, President of the LBG / c: Ludwig Boltzmann Gesellschaft/APA-Fotoservice/Preiss

On the 20th of October the LBG presented two new Ludwig Boltzmann Institutes (LBI). Both LBI are the result of the fourth call for proposals for the formation of new institutes.

The following scientists were able to convince the international experts of their research programme during the ambitious peer review process: Dr. Kaan Boztug, LBI for Rare and Undiagnosed Diseases and Dr. Markus Mitterhauser, LBI for Applied Diagnostics.

We wish both directors and their teams best of luck for their future work!

Press release: Vote on research questions now: 'Open Innovation in Science' enters the next round

Under , all those with an interest have until 13 October to vote on the future research of mental illness as of the Ludwig Boltzmann Gesellschaft's 'Tell us!' initiative

Vienna, 29 September 2015 - When is a mental illness considered cured? In what form does media consumption influence mental health? What can be done to keep the symptoms that arise after discontinuation of psychotropic drugs from leading to misdiagnoses? To date, all of these questions have been inadequately addressed by the current research on mental illness. From more than 400 contributions submitted by patients, therapists and doctors, experts at the 'Tell us!' open innovation initiative have identified proposals for future research questions for which all interested parties may cast their votes online between today and 13 October, under

Press release: “Cancer Driver Gene” reduces metastasis in prostate cancer

Vienna, 22.7.2015 - A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the University of Veterinary Medicine Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.